Natixis’s Edgewise Therapeutics EWTX Stock Holding History

Natixis’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,500	Closed	-$82.7K	–	1073
2023 Q4	$82.7K	Buy	+7,500	New	+$52.7K	﹤0.01%	790

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Natixis's EWTX Position: Q1 2024 in Review

Natixis sold out of Edgewise Therapeutics (EWTX) in Q1 2024, closing a stake of 7,500 shares — an estimated $82.7K sold.

Natixis first reported a position in EWTX in Q4 2023 and held it in 1 quarter. The position peaked at $82.7K in Q4 2023. 129 funds tracked by Wall St. Rank hold EWTX as of Q1 2024.

Natixis reported no remaining Edgewise Therapeutics position as of Q1 2024 after selling out during the quarter.
Natixis sold 7,500 Edgewise Therapeutics shares in Q1 2024, an estimated $82.7K.
Natixis first reported a position in Edgewise Therapeutics in Q4 2023 and held it in 1 quarter.
Natixis's Edgewise Therapeutics position peaked at $82.7K in Q4 2023.
129 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.